Kimberly-Clark Files for EU Antitrust Approval of $40 Billion Kenvue Acquisition

Kimberly-Clark has formally submitted its proposed $40 billion acquisition of consumer health giant Kenvue for approval by European Union antitrust regulators, a critical step toward creating a global personal care and wellness powerhouse. The filing, detailed in documents on the European Commission's website, moves the blockbuster deal into a formal review process.

Regulatory Review Underway

The request for EU clearance is a standard but crucial part of the merger process for a transaction of this scale. The deal, which was first announced in November of last year, is progressing toward its targeted closing date in the second half of 2026, contingent on receiving necessary regulatory green lights.

Regulators will assess whether the combination of the two consumer goods giants could harm competition or negatively impact consumers in the European market. The outcome of this review is a significant hurdle that investors will be monitoring closely.

Strategic Rationale and Financials

Ad

Kimberly-Clark aims to significantly expand its product portfolio by integrating Kenvue's well-known brands. The acquisition would bring Tylenol pain relievers, Listerine mouthwash, and skincare lines like Aveeno and Neutrogena under its corporate umbrella.

According to statements made when the deal was announced, the combined company is projected to generate significant financial synergies and scale. Key forecasts include:

• $2.1 billion in annual cost savings.
• Total annual revenues of approximately $32 billion for the merged entity.